In line with 2CureX's commercialization strategy, the company today announces that two experienced professionals are joining its Commercial Operations team.
After the publication of the TICC trial results and with the ongoing rollout of commercial activities in multiple European countries, 2cureX seeks to speed up the penetration of IndiTreat® by adding two strong professionals to its Commercial Operations team.
Jesper comes with a long career and success record in the in
Pia is an experienced professional who has worked for companies like
"We are very proud to attract two such extraordinary professionals. Jesper and Pia are very experienced in rolling out new technologies and products into markets and have the personal drive and hands on attitude that 2cureX needs in this moment", says
"To fulfill our sales goals of IndiTreat®, it is crucial to have alliances with local commercial organizations in each country, who not only promote our products to the Oncologists but also navigate the complex administrative processes for hospitals to buy our tests. These commercial organizations are the multipliers of our sales effort and both Jesper and Pia have proven experience building and managing them".
The company also announces that
"Maarten has been very important for 2cureX in the phases previous to launching our first product. His personality and contribution to the 2cureX team will be missed and we sincerely wish him all kinds of success in his new endeavor",says
With the announced changes 2cureX is building the organizational infrastructure and skill set required to fulfill its announced targeted commercialization roadmap.
For more information about 2cureX:
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com
----
About 2cureX
2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D microtumors that functionally resemble the patient's tumor and identifies the approved cancer treatment that most effectively kills the patient's tumor. Immediately after the test, the patient is given the selected treatment.
The first IndiTreat® product in metastatic colorectal cancer is introduced to the European market. Subsequent products will help patients at different stages of colorectal cancer and other solid cancers.
The company is listed on Nasdaq First North Growth Market in
https://news.cision.com/2curex/r/2curex-appoints-2-new-vps-for-its-commercial-operations,c3372009
https://mb.cision.com/Main/16432/3372009/1435336.pdf
(c) 2021 Cision. All rights reserved., source